IONS - Ionis Pharmaceuticals, Inc.
| Previous Close | 44.790 |
| Open | 44.670 |
| Bid | 44.250 x 800 |
| Ask | 44.340 x 900 |
| Day's Range | 44.240 - 44.880 |
| 52 Week Range | 39.070 - 65.510 |
| Volume | 40,201 |
| Avg. Volume | 1,177,453 |
| Market Cap | 5.631B |
| Beta | 3.29 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.131 |
| Earnings Date | Aug 6, 2018 - Aug 10, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 58.25 |
- Zacks•yesterday
Biotech Stock Roundup: AMGN Resubmits Evenity BLA, Advaxis Soars, Regulatory Updates
It has been a pretty ho-hum week for the biotech sector with a few regulatory updates. Amgen resubmits BLA for osteoporosis drug and Advaxis surges on positive news from FDA.
Markit•5 days agoSee what the IHS Markit Score report has to say about Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals Inc NASDAQ/NGS:IONS
- Market Realist•7 days ago
Ionis’s Tegsedi Receives Marketing Authorization in Europe
Ionis Pharmaceuticals (IONS) and Akcea Therapeutics (AKCA) announced yesterday that the European Commission had approved their marketing authorization application for Tegsedi (inotersen), an antisense oligonucleotide inhibitor that blocks the production of transthyretin protein, for the treatment of stage 1 and stage 2 polyneuropathy in patients with hereditary transthyretin amyloidosis.
- Zacks•7 days ago
Bristol-Myers' Combo Drugs Get FDA Nod for Colorectal Cancer
Bristol-Myers' (BMY) Opdivo in combination with its Yervoy received the FDA approval to treat patients with metastatic colorectal cancer (mCRC) that has progressed following treatment with fluoropyrimidine, oxaliplatin and irinotecan.
- Motley Fool•7 days ago
Is Ionis Pharmaceuticals, Inc. a Buy?
One successful drug on the market. Two potential approvals on the way. Six big partners. But do the numbers add up to buying Ionis right now?
- Zacks•8 days ago
Summit Therapeutics (SMMT) Catches Eye: Stock Jumps 8.8%
Summit Therapeutics (SMMT) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
- GlobeNewswire•8 days ago
Akcea and Ionis Announce Approval of TEGSEDI(TM) (inotersen) in the European Union
Akcea Therapeutics, Inc. (AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (IONS), announced today that TEGSEDITM (inotersen) has received marketing authorization approval from the European Commission (EC) for the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hereditary transthyretin amyloidosis (hATTR). This follows the positive opinion recommending approval provided by the Committee for Medicinal Products for Human Use (CHMP) of European Medicines Agency (EMA). Click here to view the EC`s decision.
- GlobeNewswire•8 days ago
Akcea and Ionis Announce Approval of TEGSEDI™ (inotersen) in the European Union
Akcea Therapeutics, Inc. (AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (IONS), announced today that TEGSEDITM (inotersen) has received marketing authorization approval from the European Commission (EC) for the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hereditary transthyretin amyloidosis (hATTR). This follows the positive opinion recommending approval provided by the Committee for Medicinal Products for Human Use (CHMP) of European Medicines Agency (EMA).
- ACCESSWIRE•8 days ago
Free Technical Research on Intrexon and Three More Biotech Equities
LONDON, UK / ACCESSWIRE / July 11, 2018 / If you want a free Stock Review on XON sign up now at www.wallstequities.com/registration. On Tuesday, July 10, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. Seven out of nine sectors ended Tuesday's trading session in bullish territories.
- Market Realist•10 days ago
Analysts’ Estimates and Recommendations for Ionis
As discussed previously, analysts expect Ionis Pharmaceuticals’ (IONS) revenue to grow YoY (year-over-year) in 30.6% YoY to $136.0 million in Q2 2018. They expect the company to report an adjusted net loss of $24.3 million due to higher SG&A (selling, general, and administrative) and R&D (research and development) expenses, resulting in a loss per share of $0.09. The chart below shows analysts’ recommendations for Pfizer stock over the last 12 months.
- Market Realist•10 days ago
A Review of Ionis’s Revenue Stream
As discussed earlier, Ionis Pharmaceuticals’ (IONS) revenue grew 24.7% YoY (year-over-year) in Q1 2018, and analysts expect it to grow 30.6% YoY to $136.0 million in Q2 2018. The graph below shows Ionis’s commercial and R&D (research and development) revenue since Q1 2017.
- ACCESSWIRE•10 days ago
Today's Research Reports on Trending Tickers: ACADIA Pharmaceuticals and Ionis Pharmaceuticals
NEW YORK, NY / ACCESSWIRE / July 9, 2018 / U.S. equities posted solid gains on Friday, ending the week on a positive note, supported by a stronger-than-expected jobs report. The Dow Jones Industrial Average ...
- Market Realist•10 days ago
Ionis’s Quarterly Revenue Trends
Ionis Pharmaceuticals (IONS) has developed many drugs for the treatment of various life-threatening diseases through its broadly applicable drug discovery platform. As mentioned in the previous part, Ionis’s revenue grew 24.7% YoY (year-over-year) in Q1 2018. The chart below shows Ionis’s revenue since Q1 2017, and analysts’ estimate for Q2 2018.
Markit•12 days agoSee what the IHS Markit Score report has to say about Ionis Pharmaceuticals Inc.
Short interest is moderately high for IONS with between 10 and 15% of shares outstanding currently on loan. The net inflows of $2.42 billion over the last one-month into ETFs that hold IONS are not among the highest of the last year and have been slowing.
- Market Realist•13 days ago
How Ionis Pharmaceuticals’ Valuation Compares
Ionis Pharmaceuticals (IONS), an RNA1-targeted therapeutics development leader, commercializes products in collaboration with other pharmaceutical companies. In Q1 2018, Ionis’s revenue grew 24.7% YoY (year-over-year) to $144.4 million from $115.8 million.
- The Wall Street Journal•13 days ago
[$$] Dynacure Pumps War Chest to Beat Rare Muscle Diseases
Venture capitalists are betting 47 million euros ($55 million) that French startup Dynacure can keep up recent momentum in the battle against rare muscle diseases.
- Investor's Business Daily•14 days ago
Why This Biotech Company 'Dominates' Its Rival In Drug Study
Alnylam seemingly outperformed rival Ionis in tests of drugs to treat a progressive rare disease, an analyst said Thursday. Both biotech companies are making treatments for a condition known as hereditary ATTR amyloidosis.
- PR Newswire•14 days ago
New England Journal of Medicine Publishes Results from Pivotal Study of TEGSEDI™ (inotersen) for the Treatment of Hereditary ATTR Amyloidosis
Results from the study demonstrated that patients treated with TEGSEDI experienced early, sustained and highly significant benefit in both co-primary endpoints: the modified Neuropathy Impairment Score +7 (mNIS+7), a measure of neuropathic disease progression, and the Norfolk Quality of Life Questionnaire-Diabetic Neuropathy (Norfolk QoL-DN), compared to placebo-treated patients. The clinical benefits demonstrated by TEGSEDI were associated with substantial reductions in the transthyretin (TTR) protein, the underlying cause of hATTR amyloidosis. For the full text of this publication, please visit: https://www.nejm.org/doi/full/10.1056/NEJMoa1716793.
Markit•16 days agoSee what the IHS Markit Score report has to say about Ionis Pharmaceuticals Inc.
Short interest is moderately high for IONS with between 10 and 15% of shares outstanding currently on loan. This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on June 20. The net inflows of $3.45 billion over the last one-month into ETFs that hold IONS are among the highest of the last year, but the rate of growth is slowing.
Markit•26 days agoSee what the IHS Markit Score report has to say about Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals Inc NASDAQ/NGS:IONS
- Investor's Business Daily•29 days ago
Why Biogen, Ionis Could Be In Trouble As Others Move Into SMA Drugs
PTC Therapeutics spiked Wednesday after an analyst suggested it and Roche could rout Biogen and Ionis Pharmaceuticals in treating spinal muscular atrophy.
- Motley Fool•29 days ago
Don't Get Too Excited About PTC Therapeutics (Yet)
PTC Therapeutics shares are spiking following intriguing trial data; however, it's not the only competitor working on better treatments for SMA.
- Market Realist•last month
Biogen and Ionis Crash on PTC Therapeutics’ Promising Data
Biogen and Ionis Crash on PTC Therapeutics' Promising DataPTC Therapeutics presented positive data on its SMA drug under trial
- Simply Wall St.•last month
How Financially Strong Is Ionis Pharmaceuticals Inc (NASDAQ:IONS)?
Mid-caps stocks, like Ionis Pharmaceuticals Inc (NASDAQ:IONS) with a market capitalization of US$5.85B, aren’t the focus of most investors who prefer to direct their investments towards either large-cap or small-capRead More...
- Motley Fool•last month
Here's Why PTC Therapeutics Is Soaring While Biogen and Ionis Struggle
Investors value a new round of data for PTC's spinal muscular atrophy drug.
